Proliferation of Novel Cell Type Platforms in the Oncology Competitive Landscape-Part II
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
In the same week as rare disease day and a summit on CAR-TCR looking at the ‘value’ assessment for incredible new gene and cell therapies...
Considerations around ‘value’ assessment for gene and cell therapies in rare diseases was a theme addressed by several speakers, to close...
Dr. Adrian Bot (VP of Translational Medicine – Kite, a Gilead Company) provides an update on the factors determining durable responses...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net